Citations

Clear

2391 citation(s) found for "Ma, Lin".

Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma
Lakshman, Arjun , Lacy, Martha Q. , Dingli, David , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Zeldenrust, Steven R., Lust, John A., Russell, Stephen J. , Leung, Nelson , Kapoor, Prashant , Go, Ronald S. , Lin, Yi , Gonsalves, Wilson I. , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Hwa, Yi Lisa, Fonder, Amie L, Leung, Nelson , Go, Ronald S , Gonsalves, Wilson , Warsame, Rahma , Lakshman, Arjun , Russell, Stephen J , Dingli, David , Lin, Yi , Singh, Preet Paul , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | October 25, 2017 | Volume: 93 | Issue: 2 | Pages: 179-186

10.1002/ajh.24954 | PMID 29067723 Get It

AbstractExperience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE‐like regimens: VPLRs) outside TOTAL THERAPY trials is limited. We analyzed the outcomes of 141 patients with RRMM who received VPLRs at our center between 2006 and 2017 in an intent‐to‐treat analysis. Median age was 59.7 years and 66.7% of patients were male. A median of 2.2 years (range 0.02‐11.4) separated diagnosis of myeloma and inititation of VPLR. High‐risk cytogenetics were present in 52.4% patients. Patients received a median of 4 (range 1‐14) prior therapies, including stem cell transplant (SCT) in 66.7% patients. Ninety‐five (67.4%) patients received VDT PACE, 20 (14.2%) patients received VD PACE and 26 (18.4%) patients received other VPLRs. Patients received a median of 1 cycle (range 1‐9) of VPLR. We observed ≥ minimal response in 68.4%, ≥ partial response (PR) in 54.4% and ≥ very good PR in 10.3% patients. Median progression‐free survival was 3.1 months (95% CI, 1.9‐3.9) and median overall survival (OS) was 8.1 months (CI, 6.2‐9.9). One‐hundred and sixteen (82.3%) patients received some therapy after VPLR; 71 (61.2%) received systemic chemotherapy, while 45 (38.8%) underwent SCT. Median OS for those who received SCT after VPLR was 15.1 months (CI, 10.3‐20.8). Age ≥ 60 years (hazard ratio [HR] 2.3 [CI, 1.4‐3.7]; P = 0.0008) and R‐ISS III stage (HR‐ 2.4 [CI, 1.3‐4.0]; P = 0.003) predicted shorter OS in patients receiving VPLR. VPLRs are effective in heavily pre‐treated RRMM. In fit patients, SCT can be used to consolidate the response to VPLR.
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Avet‐Loiseau, Hervé , Masszi, Tamás , Viterbo, Luísa, Pour, Luděk, Palumbo, Antonio , Cavo, Michèle , Langer, Christian , Pluta, Andrzej, Nagler, Arnon , Kumar, Shaji , Ben‐Yehuda, Dina, Miguel, Jesús F. San , Berg, Deborah, Lin, Jianchang , Velde, Helgi van de , Esseltine, Dixie‐Lee, Bacco, Alessandra Di , Moreau, Philippe , Richardson, Paul G. , Moreau, Philippe , San-Miguel, Jesus , Masszi, Tamas , Bahlis, Nizar Jacques , Chng, Wee Joo , Ganly, Peter S. , Rajkumar, S. Vincent , Esseltine, Dixie‐Lee, Richardson, Paul Gerard Guy

Mayo Clinic

Blood | October 20, 2017 | Volume: 130 | Issue: 24 | Pages: 2610-2618

10.1182/blood-2017-06-791228 | PMID 29054911 Get It

Key Points IRd was associated with a consistent PFS benefit vs placebo-Rd in RRMM patients with high-risk and standard-risk cytogenetics. The addition of ixazomib to Rd overcomes the poor PFS associated with high-risk cytogenetics in patients with RRMM.
[P4–278]: DISTINCT ULTRASTRUCTURAL CHARACTERISTICS OF CAPILLARY BASAL LAMINA IN HUMAN AND MOUSE BRAINS: RELEVANCE TO MURINE MODELS OF NEUROVASCULAR DISEASE
Lin, Wen‐Lang, Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_29 | Pages: No page available

10.1016/j.jalz.2017.06.2147 Get It

60 Utility of t wave amplitude as a non-invasive risk marker of sudden cardiac death in hypertrophic cardiomyopathy
Sugrue, Alan , Killu, AM, DeSimone, CV, Chahal, C. Anwar A. , Vogt, J. J., Křemen, Václav , Hai, Jo Jo , Hodge, DO, Acker, NG, Geske, JB, Ackerman, M. J., Ommen, SR, Noseworthy, PA, Brady, PA, Geske, Jeffrey B. , Chahal, Choudhary Anwar A , Kremen, Vaclav , Geske, Jeffrey B , Killu, Ammar M. , Desimone, C, Lin, Gen‐Min , Brady, PA

Mayo Clinic

Moderated poster session 3 | October 11, 2017 | Volume: No volume available | Issue: No issue available | Pages: A35-A36

10.1136/heartjnl-2017-ics17.59 Get It

Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma
Sajed, Dipti P. , Carey, Christopher D. , Severson, Eric A. , Afrogheh, Amir , Blacklow, Stephen C. , Chau, Nicole G. , Lin, Derrick T., García, Joaquín J. , Sholl, Lynette M. , Faquin, William C , Johnson, Carl A., Krane, Jeffrey F. , Jo, Vickie Y. , Aster, Jon Christopher

Mayo Clinic

American Journal of Surgical Pathology | September 14, 2017 | Volume: 41 | Issue: 11 | Pages: 1473-1482

10.1097/pas.0000000000000945 | PMID 28914715 Get It

NOTCH1 is frequently mutated in adenoid cystic carcinoma (ACC). To test the idea that immunohistochemical (IHC) staining can identify ACCs with NOTCH1 mutations, we performed IHC for activated NOTCH1 (NICD1) in 197 cases diagnosed as ACC from 173 patients. NICD1 staining was positive in 194 cases (98%) in 2 major patterns: subset positivity, which correlated with tubular/cribriform histology; and diffuse positivity, which correlated with a solid histology. To determine the relationship between NICD1 staining and NOTCH1 mutational status, targeted exome sequencing data were obtained on 14 diffusely NICD1-positive ACC specimens from 11 patients and 15 subset NICD1-positive ACC specimens from 15 patients. This revealed NOTCH1 gain-of-function mutations in 11 of 14 diffusely NICD1-positive ACC specimens, whereas all subset-positive tumors had wild-type NOTCH1 alleles. Notably, tumors with diffuse NICD1 positivity were associated with significantly worse outcomes (P=0.003). To determine whether NOTCH1 activation is unique among tumors included in the differential diagnosis with ACC, we performed NICD1 IHC on a cohort of diverse salivary gland and head and neck tumors. High fractions of each of these tumor types were positive for NICD1 in a subset of cells, particularly in basaloid squamous cell carcinomas; however, sequencing of basaloid squamous cell carcinomas failed to identify NOTCH1 mutations. These findings indicate that diffuse NICD1 positivity in ACC correlates with solid growth pattern, the presence of NOTCH1 gain-of-function mutations, and unfavorable outcome, and suggest that staining for NICD1 can be helpful in distinguishing ACC with solid growth patterns from other salivary gland and head and neck tumors.
Spirohexene-Tetrazine Ligation Enables Bioorthogonal Labeling of Class B G Protein-Coupled Receptors in Live Cells
Ramil, Carlo P. , Dong, Maoqing , An, Peng , Lewandowski, Tracey M., Lin, Qing , Miller, Laurence J. , Lin, Qing , Yu, Zhipeng

Mayo Clinic

Journal of the American Chemical Society | September 6, 2017 | Volume: 139 | Issue: 38 | Pages: 13376-13386

10.1021/jacs.7b05674 | PMID 28876923 Get It

Cadherin complexes recruit mRNAs and RISC to regulate epithelial cell signaling
Kourtidis, Antonis , Necela, Brian M. , Lin, Wan-Hsin, Lu, Ruifeng , Feathers, Ryan W. , Asmann, Yan W. , Thompson, E. Aubrey , Anastasiadis, Panos Z. , Necela, Brian , Lin, Wan‐Hsin

Mayo Clinic

Journal of Cell Biology | September 6, 2017 | Volume: 216 | Issue: 10 | Pages: 3073-3085

10.1083/jcb.201612125 | PMID 28877994 Get It

Cumulative evidence demonstrates that most RNAs exhibit specific subcellular distribution. However, the mechanisms regulating this phenomenon and its functional consequences are still under investigation. Here, we reveal that cadherin complexes at the apical zonula adherens (ZA) of epithelial adherens junctions recruit the core components of the RNA-induced silencing complex (RISC) Ago2, GW182, and PABPC1, as well as a set of 522 messenger RNAs (mRNAs) and 28 mature microRNAs (miRNAs or miRs), via PLEKHA7. Top canonical pathways represented by these mRNAs include Wnt/β-catenin, TGF-β, and stem cell signaling. We specifically demonstrate the presence and silencing of MYC, JUN, and SOX2 mRNAs by miR-24 and miR-200c at the ZA. PLEKHA7 knockdown dissociates RISC from the ZA, decreases loading of the ZA-associated mRNAs and miRNAs to Ago2, and results in a corresponding increase of MYC, JUN, and SOX2 protein expression. The present work reveals a mechanism that directly links junction integrity to the silencing of a set of mRNAs that critically affect epithelial homeostasis.
In Vivo Noninvasive Measurement of Young’s Modulus of Elasticity in Human Eyes: A Feasibility Study
Sit, Arthur J. , Lin, Shuai-Chun, Kazemi, Arash, McLaren, Jay W. , Pruet, Christopher M. , Zhang, Xiaoming , Zhang, Xiaoming , Kazemi, Arash, Sit, Arthur J

Mayo Clinic

Journal of Glaucoma | August 29, 2017 | Volume: 26 | Issue: 11 | Pages: 967-973

10.1097/ijg.0000000000000774 | PMID 28858155 Get It

Purpose: Abnormal ocular biomechanical properties may be important for understanding the risk of glaucoma. However, there are no clinical methods for measuring standard material properties in patients. In this feasibility study we demonstrated proof-of-principle for a novel method, ultrasound surface wave elastography (USWE), to determine the in vivo Young’s modulus of elasticity of corneas in normal human eyes. Methods: In total, 20 eyes of 10 healthy subjects (mean age, 51.4±7.2; ±SD; range, 43 to 64 y) were studied. A spherical-tipped probe (3-mm diameter) was placed on closed eyelids and generated a gentle harmonic vibration at 100 Hz for 0.1 second. Wave speed propagation in the cornea was measured by USWE, and Young’s modulus was calculated from the wave speed. Associations between Young’s modulus and intraocular pressure (IOP), age, central corneal thickness, and axial length were explored by the Pearson correlation. Statistical significance was determined by using generalized estimating equation models to account for possible correlation between fellow eyes. Results: Mean IOP was 12.8±2.7 mm Hg. Mean wave speed in the cornea was 1.82±0.10 m/s. Young’s modulus of elasticity was 696±113 kPa and was correlated with IOP (r=0.57; P=0.004), but none of the other variables (P>0.1). Conclusions: USWE is a novel noninvasive technique for measuring ocular biomechanical properties. Corneal Young’s modulus in normal eyes is associated with IOP, consistent with measurements in cadaver eyes. Further work is needed to determine elasticity in other ocular tissues, particularly the sclera, and if elasticity is altered in glaucoma patients.
Empowering Mayo Clinic Individualized Medicine with Genomic Data Warehousing
Horton, Iain, Lin, Yaxiong, Reed, Gay, Wiepert, Mathieu, Hart, Steven N. , Hart, Steven N

Mayo Clinic

Journal of Personalized Medicine | August 22, 2017 | Volume: 7 | Issue: 3 | Pages: 7

10.3390/jpm7030007 | PMID 28829408 Get It

Individualized medicine enables better diagnoses and treatment decisions for patients and promotes research in understanding the molecular underpinnings of disease. Linking individual patient’s genomic and molecular information with their clinical phenotypes is crucial to these efforts. To address this need, the Center for Individualized Medicine at Mayo Clinic has implemented a genomic data warehouse and a workflow management system to bring data from institutional electronic health records and genomic sequencing data from both clinical and research bioinformatics sources into the warehouse. The system is the foundation for Mayo Clinic to build a suite of tools and interfaces to support various clinical and research use cases. The genomic data warehouse is positioned to play a key role in enhancing the research capabilities and advancing individualized patient care at Mayo Clinic.
Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials
Lakshman, Arjun , Abeykoon, Jithma P. , Kumar, Shaji , Dingli, David , Gonsalves, Wilson I. , Leung, Nelson , Kourelis, Taxiarchis , Go, Ronald S. , Lacy, Martha Q. , Hobbs, Miriam, Lin, Yi , Warsame, Rahma , Lust, John A., Fonder, Amie , Hwa, Yi L. , Hayman, Suzanne R. , Russell, Stephen J. , Kyle, Robert A. , Kapoor, Prashant , Buadi, Francis K. , Gonsalves, Wilson , Leung, Nelson , Kourelis, Taxiarchis V, Go, Ronald S , Warsame, Rahma , Lust, John, Fonder, Amie L, Lakshman, Arjun , Russell, Stephen J , Dingli, David , Lin, Yi , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | August 11, 2017 | Volume: 92 | Issue: 11 | Pages: 1146-1155

10.1002/ajh.24883 | PMID 28799231 Get It

AbstractOutside of clinical trials, experience with daratumumab‐based combination therapies (DCTs) using bortezomib (V)/lenalidomide (R)/pomalidomide (P), and dexamethasone (d) in relapsed/refractory multiple myeloma (RRMM) is limited. We reviewed the outcomes of 126 patients who received ≥ 1 cycle of any DCT. Median age at DCT initiation was 67 (range, 43‐93) years. High‐risk cytogenetics was present in 33% patients. Median number of prior therapies was 4 (range, 1‐14) and time to first DCT from diagnosis was 4.3 years (range, 0.4‐13.0). Seventeen (13%) patients were refractory to single agent daratumumab. Fifty‐two (41%), 34 (27%), 23 (18%), and 17 (14%) received DPd, DRd, DVd and “other” DCTs, respectively. Overall response rate was 47%. Median follow‐up was 5.5 months (95% CI, 4.2‐6.1). Median progression‐free survival (PFS) was 5.5 months (95% CI, 4.2‐7.8). Median overall survival was not reached (NR) with any regimen. Median PFS (months) was worst for penta‐refractory MM (n = 8) vs quadruple refractory MM (n = 18) and others (n = 100) (2.2 [95% CI, 1‐2.4] vs 3.1 [95% CI, 2.1‐NR] vs 5.9 [95% CI, 5.0‐NR]; P < .001); those who were refractory to ≥1 agents used in the DCT vs others (4.9 [95% CI, 3.1‐6.0] vs 8.2 [95% CI, 4.6‐NR]; P = .02); and those who received >2 prior therapies vs others (5.0 months [95% CI, 3.7‐5.9] vs NR [95% CI, NR‐NR]; P = .002). Non‐hematologic toxicities included infections (38%), fatigue (32%), and infusion reactions (18%). Grade 3 or higher hematological toxicities were seen in 41% of patients. DCTs are effective in RRMM. ORR and PFS in heavily pretreated patients are lower than those reported in clinical trials.